STOCK TITAN

Framework Ventures files 13D on NovaBay with 16.2% ownership

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D

Rhea-AI Filing Summary

NovaBay Pharmaceuticals (NBY): Framework Ventures filed a Schedule 13D disclosing beneficial ownership of 1,164,117 shares of Common Stock, representing 16.2% of the class, based on 6,010,749 shares outstanding as of October 1, 2025.

The position stems from 220,663 shares of Series D Non-Voting Convertible Preferred Stock, convertible into a maximum of 1,164,117 Common shares. The group reports shared voting and dispositive power over these shares. Framework LP used $6,000,000 of working capital to purchase Preferred Stock under a purchase agreement.

On October 9, 2025, Framework LP and R01 Fund LP agreed to acquire from David Lazar 441,325 Series D for $9,850,000 and rights to purchase 268,750 Series E for an additional $2,150,000 payable to the issuer, subject to stockholder approval at the October 16, 2025 annual meeting and other conditions. Conversions are limited to 19.99% of outstanding shares until approval; upon approval, each Preferred share converts into 160 Common shares, for an aggregate of 113.6 million Common shares.

Positive

  • None.

Negative

  • None.

Insights

13D discloses a 16.2% stake with contingent large convertibility.

Framework Ventures reports 16.2% beneficial ownership in NovaBay via Series D Preferred convertible into 1,164,117 Common shares. Control rights are shared, indicating coordinated decision-making among reporting persons.

A subsequent agreement with R01 Fund LP covers 441,325 Series D for $9,850,000 and rights to 268,750 Series E for an additional $2,150,000 payable to the issuer, subject to stockholder approval on October 16, 2025 and other conditions.

Conversions are capped at 19.99% of outstanding shares until approval; if approved, each Preferred converts at 160:1, aggregating 113.6 million Common shares. Actual impact depends on approval outcomes and holder actions disclosed in future company communications.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
Framework Ventures IV L.P.'s beneficial ownership of the reported securities is comprised of 220,663 shares of the Issuer's Series D Non-Voting Convertible Preferred Stock, which is convertible into a maximum of 1,164,117 shares of the Issuer's Common Stock. The reported securities may also be deemed beneficially owned by Framework Ventures IV GP LLC, Framework Ventures Management LLC, Vance Spencer and Michael Ernest Anderson, each of which or whom disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. All percentage calculations herein are based on the aggregate of 6,010,749 shares of Common Stock outstanding as of October 1, 2025, as reported in the Issuer's Registration Statement on Form S-3, which was filed with the Securities and Exchange Commission on October 3, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
Framework Ventures IV L.P.'s beneficial ownership of the reported securities is comprised of 220,663 shares of the Issuer's Series D Non-Voting Convertible Preferred Stock, which is convertible into a maximum of 1,164,117 shares of the Issuer's Common Stock. The reported securities may also be deemed beneficially owned by Framework Ventures IV GP LLC, Framework Ventures Management LLC, Vance Spencer and Michael Ernest Anderson, each of which or whom disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. All percentage calculations herein are based on the aggregate of 6,010,749 shares of Common Stock outstanding as of October 1, 2025, as reported in the Issuer's Registration Statement on Form S-3, which was filed with the Securities and Exchange Commission on October 3, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
Framework Ventures IV L.P.'s beneficial ownership of the reported securities is comprised of 220,663 shares of the Issuer's Series D Non-Voting Convertible Preferred Stock, which is convertible into a maximum of 1,164,117 shares of the Issuer's Common Stock. The reported securities may also be deemed beneficially owned by Framework Ventures IV GP LLC, Framework Ventures Management LLC, Vance Spencer and Michael Ernest Anderson, each of which or whom disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. All percentage calculations herein are based on the aggregate of 6,010,749 shares of Common Stock outstanding as of October 1, 2025, as reported in the Issuer's Registration Statement on Form S-3, which was filed with the Securities and Exchange Commission on October 3, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
Framework Ventures IV L.P.'s beneficial ownership of the reported securities is comprised of 220,663 shares of the Issuer's Series D Non-Voting Convertible Preferred Stock, which is convertible into a maximum of 1,164,117 shares of the Issuer's Common Stock. The reported securities may also be deemed beneficially owned by Framework Ventures IV GP LLC, Framework Ventures Management LLC, Vance Spencer and Michael Ernest Anderson, each of which or whom disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. All percentage calculations herein are based on the aggregate of 6,010,749 shares of Common Stock outstanding as of October 1, 2025, as reported in the Issuer's Registration Statement on Form S-3, which was filed with the Securities and Exchange Commission on October 3, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
Framework Ventures IV L.P.'s beneficial ownership of the reported securities is comprised of 220,663 shares of the Issuer's Series D Non-Voting Convertible Preferred Stock, which is convertible into a maximum of 1,164,117 shares of the Issuer's Common Stock. The reported securities may also be deemed beneficially owned by Framework Ventures IV GP LLC, Framework Ventures Management LLC, Vance Spencer and Michael Ernest Anderson, each of which or whom disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. All percentage calculations herein are based on the aggregate of 6,010,749 shares of Common Stock outstanding as of October 1, 2025, as reported in the Issuer's Registration Statement on Form S-3, which was filed with the Securities and Exchange Commission on October 3, 2025.


SCHEDULE 13D


Framework Ventures IV L.P.
Signature:/s/ Michael Ernest Anderson
Name/Title:Michael Ernest Anderson / Authorized Signatory
Date:10/15/2025
Framework Ventures Management LLC
Signature:/s/ Michael Ernest Anderson
Name/Title:Michael Ernest Anderson / Authorized Signatory
Date:10/15/2025
Framework Ventures IV GP LLC
Signature:/s/ Michael Ernest Anderson
Name/Title:Michael Ernest Anderson / Authorized Signatory
Date:10/15/2025
Vance Spencer
Signature:/s/ Vance Spencer
Name/Title:Vance Spencer
Date:10/15/2025
Michael Ernest Anderson
Signature:/s/ Michael Ernest Anderson
Name/Title:Michael Ernest Anderson
Date:10/15/2025

FAQ

What stake did Framework Ventures disclose in NovaBay (NBY)?

They reported beneficial ownership of 1,164,117 Common shares, representing 16.2% of the class.

What is the source of Framework’s NovaBay stake?

It comes from 220,663 Series D Non-Voting Convertible Preferred shares, convertible into up to 1,164,117 Common shares.

What transactions did Framework and R01 agree to regarding NovaBay preferred stock?

They agreed to acquire 441,325 Series D for $9,850,000 and rights to 268,750 Series E for an additional $2,150,000 payable to the issuer.

Are there limits on converting NovaBay preferred shares?

Yes. Conversions are limited to 19.99% of outstanding shares until stockholders approve; each Preferred share then converts into 160 Common shares.

When is the stockholder vote tied to these NovaBay transactions?

The annual meeting is on October 16, 2025, with proposals referenced in the September 23, 2025 definitive proxy statement.

What share count was used to calculate Framework’s ownership percentage?

Based on 6,010,749 Common shares outstanding as of October 1, 2025.

How much capital did Framework LP deploy for its preferred stock purchase?

Framework LP used $6,000,000 of working capital under the purchase agreement.
Novabay Pharma

NYSE:NBY

NBY Rankings

NBY Latest News

NBY Latest SEC Filings

NBY Stock Data

56.28M
6.17M
Biotechnology
Pharmaceutical Preparations
Link
United States
EMERYVILLE